CZ297994B6 - Proforma léciv k terapii tumoru a zánetlivých onemocnení - Google Patents

Proforma léciv k terapii tumoru a zánetlivých onemocnení Download PDF

Info

Publication number
CZ297994B6
CZ297994B6 CZ0074297A CZ74297A CZ297994B6 CZ 297994 B6 CZ297994 B6 CZ 297994B6 CZ 0074297 A CZ0074297 A CZ 0074297A CZ 74297 A CZ74297 A CZ 74297A CZ 297994 B6 CZ297994 B6 CZ 297994B6
Authority
CZ
Czechia
Prior art keywords
formula
compound
glycosyl
amino
active
Prior art date
Application number
CZ0074297A
Other languages
Czech (cs)
English (en)
Other versions
CZ74297A3 (en
Inventor
Bosslet@Klaus
Czech@Jörg
Gerken@Manfred
Straub@Rainer
Monneret@Claude
Claude Florent@Jean
Schmidt@Frederic
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ297994(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of CZ74297A3 publication Critical patent/CZ74297A3/cs
Publication of CZ297994B6 publication Critical patent/CZ297994B6/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CZ0074297A 1996-03-12 1997-03-11 Proforma léciv k terapii tumoru a zánetlivých onemocnení CZ297994B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96103866 1996-03-12

Publications (2)

Publication Number Publication Date
CZ74297A3 CZ74297A3 (en) 1997-09-17
CZ297994B6 true CZ297994B6 (cs) 2007-05-16

Family

ID=8222555

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ0074297A CZ297994B6 (cs) 1996-03-12 1997-03-11 Proforma léciv k terapii tumoru a zánetlivých onemocnení

Country Status (24)

Country Link
US (1) US5935995A (https=)
EP (1) EP0795334B1 (https=)
JP (1) JP4392065B2 (https=)
KR (1) KR100466467B1 (https=)
CN (1) CN1168733C (https=)
AT (1) ATE316799T1 (https=)
AU (1) AU708202B2 (https=)
BG (1) BG61900B1 (https=)
BR (1) BRPI9701248B1 (https=)
CA (1) CA2199664C (https=)
CZ (1) CZ297994B6 (https=)
DE (1) DE59712561D1 (https=)
DK (1) DK0795334T3 (https=)
ES (1) ES2257756T3 (https=)
HU (1) HU228764B1 (https=)
NO (1) NO320322B1 (https=)
NZ (1) NZ314368A (https=)
PL (1) PL189604B1 (https=)
RO (1) RO120951B1 (https=)
RU (1) RU2191021C2 (https=)
SG (1) SG50011A1 (https=)
SI (1) SI0795334T1 (https=)
TR (1) TR199700178A2 (https=)
UA (1) UA50719C2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
IL138990A0 (en) * 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
DE10058596A1 (de) * 2000-11-25 2002-06-06 Aventis Pharma Gmbh Verfahren zum Screening von chemischen Verbindungen zur Modulierung der Wechselwirkung einer EVH1-Domäne oder eines Proteins mit einer EVH1-Domäne mit einer EVH1-Bindedomäne oder einem Protein mit einer EVH1-Bindedomäne sowie ein Verfahren zum Nachweis besagter Wechselwirkung
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
WO2003018549A2 (en) * 2001-08-30 2003-03-06 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
EP1541579A1 (en) * 2002-06-20 2005-06-15 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
EP1734962A4 (en) * 2004-03-30 2010-07-14 Painceptor Pharma Corp COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
CN102746336B (zh) * 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
ES2547302T3 (es) * 2007-04-06 2015-10-05 Ziopharm Oncology, Inc. Sales de mostaza de isofosforamida y análogos de las mismas
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
BR112012004720B1 (pt) * 2009-09-02 2021-06-29 Auckland Uniservices Limited Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 a-i 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
AU2016359234B2 (en) 2015-11-25 2022-09-08 Ligachem Biosciences Inc. Conjugates comprising peptide groups and methods related thereto
KR102847350B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
PE20210367A1 (es) 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
JP7459063B2 (ja) 2018-05-09 2024-04-01 レゴケム バイオサイエンシズ, インク. 抗-cd19抗体薬物複合体に関連する組成物および方法
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007929A1 (en) * 1989-01-23 1990-07-26 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
EP0501215A2 (de) * 1991-02-28 1992-09-02 BEHRINGWERKE Aktiengesellschaft Monoklonalantikörper, Linker- und Beta-Glucuronidase enthaltende Fusionsproteine zur Prodrug-Aktivierung, ihre Herstellung und Verwendung
EP0511917A1 (fr) * 1991-04-30 1992-11-04 Laboratoires Hoechst S.A. Prodrogues glycosylées, leur procédé de préparation et leurs utilisations
CA2081181A1 (en) * 1991-10-25 1993-04-26 Leon Fairfield Chamberlain Single-ended low-pressure discharge lamp
EP0595133A2 (de) * 1992-10-27 1994-05-04 BEHRINGWERKE Aktiengesellschaft Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0642799A1 (en) * 1993-09-09 1995-03-15 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
CA2081281A1 (en) * 1992-10-23 1994-04-24 Shing-Ming Wang Activation of glucuronide prodrugs by ligand-beta-glucuronidase conjugates for chemotherapy
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007929A1 (en) * 1989-01-23 1990-07-26 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
EP0501215A2 (de) * 1991-02-28 1992-09-02 BEHRINGWERKE Aktiengesellschaft Monoklonalantikörper, Linker- und Beta-Glucuronidase enthaltende Fusionsproteine zur Prodrug-Aktivierung, ihre Herstellung und Verwendung
EP0511917A1 (fr) * 1991-04-30 1992-11-04 Laboratoires Hoechst S.A. Prodrogues glycosylées, leur procédé de préparation et leurs utilisations
CA2081181A1 (en) * 1991-10-25 1993-04-26 Leon Fairfield Chamberlain Single-ended low-pressure discharge lamp
EP0595133A2 (de) * 1992-10-27 1994-05-04 BEHRINGWERKE Aktiengesellschaft Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0642799A1 (en) * 1993-09-09 1995-03-15 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation

Also Published As

Publication number Publication date
HU228764B1 (en) 2013-05-28
CN1168733C (zh) 2004-09-29
HU9700579D0 (en) 1997-04-28
AU708202B2 (en) 1999-07-29
CN1163895A (zh) 1997-11-05
SG50011A1 (en) 1998-06-15
NZ314368A (en) 1998-10-28
HUP9700579A2 (en) 1997-12-29
CA2199664A1 (en) 1997-09-12
TR199700178A2 (tr) 1997-09-21
SI0795334T1 (sl) 2006-06-30
BG101290A (en) 1997-09-30
CZ74297A3 (en) 1997-09-17
DE59712561D1 (de) 2006-04-13
EP0795334B1 (de) 2006-02-01
MX9701832A (es) 1998-07-31
NO971116D0 (no) 1997-03-11
BG61900B1 (bg) 1998-09-30
BR9701248A (pt) 1999-10-13
ATE316799T1 (de) 2006-02-15
JP4392065B2 (ja) 2009-12-24
BR9701248A8 (pt) 2013-06-18
RU2191021C2 (ru) 2002-10-20
EP0795334A2 (de) 1997-09-17
UA50719C2 (uk) 2002-11-15
CA2199664C (en) 2008-05-20
PL189604B1 (pl) 2005-08-31
US5935995A (en) 1999-08-10
NO320322B1 (no) 2005-11-21
EP0795334A3 (de) 1997-09-24
JPH101495A (ja) 1998-01-06
ES2257756T3 (es) 2006-08-01
HUP9700579A3 (en) 1999-05-28
KR100466467B1 (ko) 2005-06-29
AU1620597A (en) 1997-09-18
DK0795334T3 (da) 2006-06-06
PL318878A1 (en) 1997-09-15
BRPI9701248B1 (pt) 2022-01-18
NO971116L (no) 1997-09-15
RO120951B1 (ro) 2006-10-30
KR970065550A (ko) 1997-10-13

Similar Documents

Publication Publication Date Title
CZ297994B6 (cs) Proforma léciv k terapii tumoru a zánetlivých onemocnení
US6146658A (en) Prodrugs, their preparation and use as pharmaceuticals
EP2041140B1 (en) Aziridinyl-epothilone compounds
ES3029483T3 (en) Folate receptor binding conjugates of antifolates
JP2002517422A (ja) 多価のマクロライド系抗生物質
BR112019022445A2 (pt) Composição de conjugado ligante-fármaco, formulação, método para inibir a multiplicação de uma célula tumoral ou célula cancerosa ou causar apoptose em uma célula tumoral ou cancerosa, e, composto de conector de fármaco
CN120957753A (zh) 生物活性结合物、其制备方法和其用途
US6479498B1 (en) Sodium channel drugs and uses
US20160128321A1 (en) Ladder-Frame Polyether Conjugates
Cogan et al. Doxsaliform: A novel N-Mannich base prodrug of a doxorubicin formaldehyde conjugate
US8183228B2 (en) Anticoagulant antithrombotic dual inhibitors comprising a biotin label
MXPA97001832A (en) New profarmacos for inflamator tumors and disease therapy
KR20260028651A (ko) 엽산-약물 접합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
EP3310787B9 (en) Taggable heteroaromatic drugs and conjugates thereof
KR20150101436A (ko) 케르세틴-아미노산 접합체를 포함하는 항암 및 항생제 내성 억제효능을 보이는 조성물 및 그 방법
CZ298676B6 (cs) Nosice léciv na bázi modifikovaných poly(ethylenglykolu) a jejich pH-senzitivní konjugáty
JPH06508114A (ja) パリトキシン関連プロドラッグおよびその投与方法

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20150311